Background: Chronic heart failure with reduced ejection fraction impairs health-related
quality of life (HRQL). Omecamtiv mecarbil (OM)—a novel activator of cardiac myosin …

A central factor in the pathogenesis of heart failure (HF) with reduced ejection fraction is the
initial decrease in systolic function. Prior attempts at increasing cardiac contractility with oral …

Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …

Importance Exercise limitation is a cardinal manifestation of heart failure with reduced
ejection fraction (HFrEF) but is not consistently improved by any of the current guideline …

Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv
mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested …

Background Omecamtiv mecarbil (OM) is a direct myosin activator that augments left
ventricular systolic function. This review compares OM to placebo by evaluating its effect on …

Background: Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases
myocardial function in healthy volunteers and in patients with chronic heart failure …

Although impairment of myocardial contractility is a central factor of heart failure (HF)
progression, current inotropic agents have consistently failed to show beneficial effects with …

Heart failure (HF) is a major public health problem in the United States as well as worldwide.
Chronic heart failure is a syndrome of reduced cardiac output resulting from impaired …

Heart failure continues to be a major global health problem with a pronounced impact on
morbidity and mortality and very limited drug treatment options especially with regard to …